# Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery

> **NCT05084573** · PHASE3 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 92 (estimated)

## Conditions studied

- Shoulder Fractures

## Interventions

- **DRUG:** Liposomal bupivacaine
- **DRUG:** Standard bupivacaine

## Key facts

- **NCT ID:** NCT05084573
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-07-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084573, "Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05084573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*